Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.12, Zacks reports.
Olema Pharmaceuticals Stock Performance
Shares of NASDAQ OLMA traded up $0.11 during trading hours on Friday, reaching $4.23. 2,079,395 shares of the stock were exchanged, compared to its average volume of 807,025. The firm has a market capitalization of $242.37 million, a price-to-earnings ratio of -1.93 and a beta of 2.11. Olema Pharmaceuticals has a 52 week low of $3.94 and a 52 week high of $16.62. The stock's fifty day simple moving average is $5.09 and its 200 day simple moving average is $8.35.
Analyst Ratings Changes
Several analysts have issued reports on the company. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday. Oppenheimer restated an "outperform" rating and issued a $25.00 price objective (down previously from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday.
Check Out Our Latest Analysis on OLMA
Insider Transactions at Olema Pharmaceuticals
In related news, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of Olema Pharmaceuticals stock in a transaction that occurred on Wednesday, January 8th. The shares were acquired at an average price of $5.76 per share, with a total value of $1,728,000.00. Following the completion of the transaction, the insider now directly owns 7,800,000 shares of the company's stock, valued at $44,928,000. This represents a 4.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 19.40% of the stock is owned by corporate insiders.
About Olema Pharmaceuticals
(
Get Free Report)
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Further Reading
Before you consider Olema Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.
While Olema Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
